Covered recipient · General Payments record
KIMBERLY C PENDLEY
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$1,247.02
- Reported across 48 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $626.99 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $286.74 | 4 |
| GlaxoSmithKline, LLC. | $142.49 | 2 |
| Amgen Inc. | $107.08 | 4 |
| ABBVIE INC. | $29.23 | 2 |
| Echosens North America, Inc. | $17.86 | 1 |
| Corcept Therapeutics | $15.76 | 1 |
| Esperion Therapeutics, Inc. | $14.63 | 1 |
| DEXCOM, INC. | $13.20 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.82 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107831260 | CMS |
| ABBVIE INC. | $14.41 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107831262 | CMS |
| Amgen Inc. | $13.71 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117652884 | CMS |
| Amgen Inc. | $15.48 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117652880 | CMS |
| Amgen Inc. | $56.68 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117350941 | CMS |
| Amgen Inc. | $21.21 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117652882 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.81 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104423293 | CMS |
| AstraZeneca Pharmaceuticals LP | $28.21 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104756834 | CMS |
| AstraZeneca Pharmaceuticals LP | $120.72 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105751813 | CMS |
| AstraZeneca Pharmaceuticals LP | $120.00 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105216017 | CMS |
| Corcept Therapeutics | $15.76 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117750529 | CMS |
| Dexcom, Inc. | $13.20 | 12/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153372039 | CMS |
| Echosens North America, Inc. | $17.86 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154982462 | CMS |
| Esperion Therapeutics, Inc. | $14.63 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129473956 | CMS |
| GlaxoSmithKline, LLC. | $17.49 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116357070 | CMS |
| GlaxoSmithKline, LLC. | $125.00 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116583095 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.